Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor
Top Cited Papers
Open Access
- 27 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (9), 1033-1043
- https://doi.org/10.1182/blood.2019004465
Abstract
Neutropenia and neutrophil dysfunction cause serious infections and inflammatory bowel disease in glycogen storage disease type Ib (GSD-Ib). Our discovery that accumulating 1,5-anhydroglucitol-6-phosphate (1,5AG6P) caused neutropenia in a glucose-6-phosphatase 3 (G6PC3)-deficient mouse model and in 2 rare diseases (GSD-Ib and G6PC3 deficiency) led us to repurpose the widely used antidiabetic drug empagliflozin, an inhibitor of the renal glucose cotransporter sodium glucose cotransporter 2 (SGLT2). Off-label use of empagliflozin in 4 GSD-Ib patients with incomplete response to granulocyte colony-stimulating factor (GCSF) treatment decreased serum 1,5AG and neutrophil 1,5AG6P levels within 1 month. Clinically, symptoms of frequent infections, mucosal lesions, and inflammatory bowel disease resolved, and no symptomatic hypoglycemia was observed. GCSF could be discontinued in 2 patients and tapered by 57% and 81%, respectively, in the other 2. The fluctuating neutrophil numbers in all patients were increased and stabilized. We further demonstrated improved neutrophil function: normal oxidative burst (in 3 of 3 patients tested), corrected protein glycosylation (2 of 2), and normal neutrophil chemotaxis (1 of 1), and bactericidal activity (1 of 1) under treatment. In summary, the glucose-lowering SGLT2 inhibitor empagliflozin, used for type 2 diabetes, was successfully repurposed for treating neutropenia and neutrophil dysfunction in the rare inherited metabolic disorder GSD-Ib without causing symptomatic hypoglycemia. We ascribe this to an improvement in neutrophil function resulting from the reduction of the intracellular concentration of 1,5AG6P.Keywords
This publication has 42 references indexed in Scilit:
- G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunctionGlycobiology, 2011
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010
- A Syndrome with Congenital Neutropenia and Mutations inG6PC3New England Journal of Medicine, 2009
- Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type IbBlood, 2008
- Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase–βJCI Insight, 2007
- Functional characterization of mitochondria in neutrophils: a role restricted to apoptosisCell Death & Differentiation, 2003
- Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b)Blood, 2003
- A Gene on Chromosome 11q23 Coding for a Putative Glucose- 6-Phosphate Translocase Is Mutated in Glycogen-Storage Disease Types Ib and IcAmerican Journal of Human Genetics, 1998
- In Vitro Bactericidal Capacity of Human Polymorphonuclear Leukocytes: Diminished Activity in Chronic Granulomatous Disease of Childhood *JCI Insight, 1967
- THE CHEMOTACTIC EFFECT OF MIXTURES OF ANTIBODY AND ANTIGEN ON POLYMORPHONUCLEAR LEUCOCYTESThe Journal of Experimental Medicine, 1962